CollPlant Terminates Development Agreement with AbbVie, Looks Ahead to 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 13 2026
0mins
The company said, "This morning, we announced the termination of our development agreement with AbbVie. While this represents the close of an important chapter, we see it as the beginning of an even more promising journey. I'd like to share our vision for what lies ahead for CollPlant in 2026. As noted, Allergan Industrie SAS, an AbbVie company, notified us that it was exercising its right to terminate the development agreement, previously entered into in February 2021, upon 60 days' advance notice. During the prior five years, AbbVie was developing a dermal and soft tissue filler product for commercialization in the medical aesthetics market, using the Company's rhCollagen technology. We view this development as an opportunity, and we are moving forward with confidence. Interest in CollPlant's collagen technology remains strong and we are actively pursuing entering into agreements with new partners, across all types of aesthetic products, including for dermal and soft tissue filler products. The market opportunity before us is significant, and we intend to capture it. Over the past few months, we have engaged with several leading strategic partners and Tier 1 corporations to explore potential joint development opportunities, primarily in the aesthetics sector. These collaborations focus on dermal filler products incorporating CollPlant's technology, hyaluronic acid, and other key components. While these discussions naturally take time, we are actively working to accelerate the process and, while there is no guarantee, are optimistic about reaching a definitive agreement in the coming months."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CLGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CLGN
About CLGN
CollPlant Biotechnologies Ltd, formerly known as Collplant Holdings Ltd, is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CollPlant Reports Q1 Earnings Results
- Earnings Report: CollPlant reported a GAAP EPS of -$0.23 for Q1, indicating challenges in profitability and reflecting ongoing financial pressures on the company.
- Revenue Performance: The company's revenue for the first quarter was only $0.07M, significantly below market expectations, suggesting that product sales and market penetration need substantial improvement for sustainable growth.
- Nasdaq Notice: CollPlant received a notice from Nasdaq regarding the minimum $1 bid price, which could negatively impact its stock liquidity and investor confidence, compelling the company to take measures to maintain its listing status.
- Historical Financial Data: Historical financial data indicates significant volatility in CollPlant's performance, prompting investors to closely monitor its future financial results and strategic adjustments to assess long-term investment value.
See More
CollPlant Reports Q1 2026 Financial Results and Corporate Update
- Financial Overview: CollPlant's Q1 2026 financial results highlight the company's ongoing focus on innovative technologies and products based on recombinant human collagen, although specific financial metrics have yet to be disclosed.
- Technological Advancements: The company is advancing its non-animal-derived recombinant human collagen (rhCollagen) technology, which could enhance its competitive edge in tissue regeneration and medical aesthetics applications, solidifying its position in the industry.
- Market Positioning: With a product line centered on regenerative medicine and medical aesthetics, CollPlant is well-positioned to capture a larger market share as consumer demand for non-animal-derived products continues to rise.
- Future Outlook: While current financial data remains undisclosed, CollPlant demonstrates strong growth potential and plans to continue driving technological innovation and market expansion to meet the increasing medical demands.
See More
CollPlant Reports Q1 2026 Financial Results and Strategic Developments
- Declining Financial Performance: CollPlant reported GAAP revenues of $73,000 for Q1 2026, a significant drop from $2.1 million in Q1 2025, primarily due to the absence of a $2 million development milestone payment recognized in the previous year, indicating instability in revenue sources that may affect future financing capabilities.
- R&D Advancements: The company is advancing the development of its next-generation photocurable dermal filler based on rhCollagen technology, designed to provide immediate structural support and promote long-term tissue regeneration, currently in the final preclinical stage, expected to meet market demand for anti-aging products and enhance competitive positioning.
- Strategic Partnership Exploration: CollPlant is engaging in discussions with several strategic partners to explore joint development and commercialization opportunities in the medical aesthetics field, with high levels of interest indicating market recognition of its technology, potentially laying the groundwork for future revenue growth.
- Cost Control Measures: The company implemented a cost reduction plan in Q1, reducing operating expenses from $3.5 million to $2.9 million, primarily through workforce reductions and decreased R&D spending, which helps improve financial discipline, although it may impact R&D progress in the short term.
See More
CollPlant Ends AbbVie Partnership, Eyes New Opportunities Ahead
- Partnership Termination: CollPlant announced the termination of its development agreement with AbbVie, viewing this end as a new beginning, as the company actively seeks new strategic partners in the medical aesthetics market for 2026.
- Cost Optimization Plan: To ensure future positioning, CollPlant is implementing a cost-reduction and workforce optimization plan, aiming to reduce its workforce by approximately 50%, which is expected to extend the company's cash runway into Q4 2026, thereby laying the groundwork for achieving key milestones.
- Technological Innovation: CollPlant is developing photocurable dermal filler technology designed to create a stable crosslinked scaffold through light activation, with plans to initiate clinical trials within two years, aiming to commercialize next-generation regenerative aesthetic solutions.
- BioInk Product Line: CollPlant launched BioFlex, a kit designed for 3D bioprinting applications using plant-derived recombinant human collagen, providing a sustainable alternative for research, and is expected to attract collaborations with leading research institutions to expand market influence.
See More
CollPlant Biotechnologies Reports FY 2025 Financial Results
- Financial Performance: CollPlant Biotechnologies reported a FY 2025 non-GAAP EPS of -$0.83, despite a remarkable 355.8% year-over-year revenue increase to $2.37 million, indicating potential in revenue growth but ongoing profitability challenges.
- Cash Flow Status: As of December 31, 2025, the company had $5.6 million in cash and cash equivalents, with cash used in operating activities reduced to $9.4 million from $14.1 million in 2024, suggesting some progress in cost management.
- Market Warning: CollPlant received a Nasdaq notice regarding a minimum bid price of $1, which poses a threat to its stock price stability, potentially affecting investor confidence and limiting future financing capabilities.
- Quant Rating: Seeking Alpha's Quant Rating on CollPlant reflects a cautious market outlook on its future performance, highlighting investor concerns regarding the company's long-term profitability.
See More
CollPlant Reports 2025 Financial Results and Corporate Updates
- Financial Performance Boost: CollPlant's GAAP revenue for 2025 reached $2.4 million, significantly up from $515,000 in 2024, primarily driven by a $2 million milestone payment from AbbVie, highlighting the company's commercial potential in regenerative medicine.
- Product Line Expansion: The company successfully broadened its distribution network in North America through a new partnership with a U.S. logistics center, enhancing market coverage for its rhCollagen and BioInk product lines, which is expected to further drive sales growth.
- Technological Innovation: Researchers at Mayo Clinic developed the first fully humanized 3D bioprinted skin model using CollPlant's rhCollagen, providing a sustainable alternative to animal testing, which is anticipated to drive market opportunities in bioprinting and tissue engineering, with a market size of approximately $100 million projected to grow over 10% annually.
- Intellectual Property Enhancement: CollPlant secured new patents related to its photocurable dermal filler technology in the U.S. and South Korea, further strengthening its intellectual property position in the aesthetic medicine market, which is expected to provide robust legal protection for future commercial applications.
See More
CollPlant Reports Q1 Earnings Results
- Earnings Report: CollPlant reported a GAAP EPS of -$0.23 for Q1, indicating challenges in profitability and reflecting ongoing financial pressures on the company.
- Revenue Performance: The company's revenue for the first quarter was only $0.07M, significantly below market expectations, suggesting that product sales and market penetration need substantial improvement for sustainable growth.
- Nasdaq Notice: CollPlant received a notice from Nasdaq regarding the minimum $1 bid price, which could negatively impact its stock liquidity and investor confidence, compelling the company to take measures to maintain its listing status.
- Historical Financial Data: Historical financial data indicates significant volatility in CollPlant's performance, prompting investors to closely monitor its future financial results and strategic adjustments to assess long-term investment value.
See More
CollPlant Reports Q1 2026 Financial Results and Corporate Update
- Financial Overview: CollPlant's Q1 2026 financial results highlight the company's ongoing focus on innovative technologies and products based on recombinant human collagen, although specific financial metrics have yet to be disclosed.
- Technological Advancements: The company is advancing its non-animal-derived recombinant human collagen (rhCollagen) technology, which could enhance its competitive edge in tissue regeneration and medical aesthetics applications, solidifying its position in the industry.
- Market Positioning: With a product line centered on regenerative medicine and medical aesthetics, CollPlant is well-positioned to capture a larger market share as consumer demand for non-animal-derived products continues to rise.
- Future Outlook: While current financial data remains undisclosed, CollPlant demonstrates strong growth potential and plans to continue driving technological innovation and market expansion to meet the increasing medical demands.
See More
CollPlant Reports Q1 2026 Financial Results and Strategic Developments
- Declining Financial Performance: CollPlant reported GAAP revenues of $73,000 for Q1 2026, a significant drop from $2.1 million in Q1 2025, primarily due to the absence of a $2 million development milestone payment recognized in the previous year, indicating instability in revenue sources that may affect future financing capabilities.
- R&D Advancements: The company is advancing the development of its next-generation photocurable dermal filler based on rhCollagen technology, designed to provide immediate structural support and promote long-term tissue regeneration, currently in the final preclinical stage, expected to meet market demand for anti-aging products and enhance competitive positioning.
- Strategic Partnership Exploration: CollPlant is engaging in discussions with several strategic partners to explore joint development and commercialization opportunities in the medical aesthetics field, with high levels of interest indicating market recognition of its technology, potentially laying the groundwork for future revenue growth.
- Cost Control Measures: The company implemented a cost reduction plan in Q1, reducing operating expenses from $3.5 million to $2.9 million, primarily through workforce reductions and decreased R&D spending, which helps improve financial discipline, although it may impact R&D progress in the short term.
See More
CollPlant Ends AbbVie Partnership, Eyes New Opportunities Ahead
- Partnership Termination: CollPlant announced the termination of its development agreement with AbbVie, viewing this end as a new beginning, as the company actively seeks new strategic partners in the medical aesthetics market for 2026.
- Cost Optimization Plan: To ensure future positioning, CollPlant is implementing a cost-reduction and workforce optimization plan, aiming to reduce its workforce by approximately 50%, which is expected to extend the company's cash runway into Q4 2026, thereby laying the groundwork for achieving key milestones.
- Technological Innovation: CollPlant is developing photocurable dermal filler technology designed to create a stable crosslinked scaffold through light activation, with plans to initiate clinical trials within two years, aiming to commercialize next-generation regenerative aesthetic solutions.
- BioInk Product Line: CollPlant launched BioFlex, a kit designed for 3D bioprinting applications using plant-derived recombinant human collagen, providing a sustainable alternative for research, and is expected to attract collaborations with leading research institutions to expand market influence.
See More
CollPlant Biotechnologies Reports FY 2025 Financial Results
- Financial Performance: CollPlant Biotechnologies reported a FY 2025 non-GAAP EPS of -$0.83, despite a remarkable 355.8% year-over-year revenue increase to $2.37 million, indicating potential in revenue growth but ongoing profitability challenges.
- Cash Flow Status: As of December 31, 2025, the company had $5.6 million in cash and cash equivalents, with cash used in operating activities reduced to $9.4 million from $14.1 million in 2024, suggesting some progress in cost management.
- Market Warning: CollPlant received a Nasdaq notice regarding a minimum bid price of $1, which poses a threat to its stock price stability, potentially affecting investor confidence and limiting future financing capabilities.
- Quant Rating: Seeking Alpha's Quant Rating on CollPlant reflects a cautious market outlook on its future performance, highlighting investor concerns regarding the company's long-term profitability.
See More
CollPlant Reports 2025 Financial Results and Corporate Updates
- Financial Performance Boost: CollPlant's GAAP revenue for 2025 reached $2.4 million, significantly up from $515,000 in 2024, primarily driven by a $2 million milestone payment from AbbVie, highlighting the company's commercial potential in regenerative medicine.
- Product Line Expansion: The company successfully broadened its distribution network in North America through a new partnership with a U.S. logistics center, enhancing market coverage for its rhCollagen and BioInk product lines, which is expected to further drive sales growth.
- Technological Innovation: Researchers at Mayo Clinic developed the first fully humanized 3D bioprinted skin model using CollPlant's rhCollagen, providing a sustainable alternative to animal testing, which is anticipated to drive market opportunities in bioprinting and tissue engineering, with a market size of approximately $100 million projected to grow over 10% annually.
- Intellectual Property Enhancement: CollPlant secured new patents related to its photocurable dermal filler technology in the U.S. and South Korea, further strengthening its intellectual property position in the aesthetic medicine market, which is expected to provide robust legal protection for future commercial applications.
See More
